David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Home BancShares
HOMB
$5.97B
| $1.07M | ﹤0.01% |
+61,114
| New | +$1.13M |
|
2527
CALL
Goodyear
GT
$1.8B
| $1.07M | ﹤0.01% |
58,800
-100,700
| -63% | -$1.96M |
|
2528
CALL
Talos Energy
TALO
$2.79B
| $1.06M | ﹤0.01% |
40,000
+25,000
| +167% | +$542K |
|
2529
Zumiez
ZUMZ
$311M
| $1.06M | ﹤0.01% |
42,678
-16,887
| -28% | -$400K |
|
2530
CALL
Herbalife
HLF
$1.3B
| $1.06M | ﹤0.01% |
20,000
-267,200
| -93% | -$15.3M |
|
|
IMMU
2531
DELISTED
Immunomedics Inc
IMMU
| $1.06M | ﹤0.01% |
+55,174
| New | +$889K |
|
2532
CALL
PBF Energy
PBF
$8.27B
| $1.06M | ﹤0.01% |
34,000
-34,900
| -51% | -$1.17M |
|
|
SKX
2533
DELISTED
Skechers
SKX
| $1.06M | ﹤0.01% |
31,485
-66,210
| -68% | -$1.98M |
|
2534
Tilly's
TLYS
$120M
| $1.06M | ﹤0.01% |
94,946
-12,770
| -12% | -$151K |
|
2535
Extra Space Storage
EXR
$30.4B
| $1.05M | ﹤0.01% |
10,304
-134,130
| -93% | -$12.9M |
|
2536
Pricesmart
PSMT
$5.41B
| $1.05M | ﹤0.01% |
+17,829
| New | +$1.11M |
|
2537
Alnylam Pharmaceuticals
ALNY
$32B
| $1.05M | ﹤0.01% |
11,214
-25,604
| -70% | -$2.14M |
|
2538
EXL Service
EXLS
$5.69B
| $1.05M | ﹤0.01% |
87,295
+28,690
| +49% | +$336K |
|
2539
Southside Bancshares
SBSI
$956M
| $1.05M | ﹤0.01% |
31,488
+23,679
| +303% | +$803K |
|
|
AEGN
2540
DELISTED
Aegion Corp
AEGN
| $1.05M | ﹤0.01% |
59,526
-21,104
| -26% | -$383K |
|
2541
PUT
Assurant
AIZ
$14.2B
| $1.04M | ﹤0.01% |
+11,000
| New | +$1.06M |
|
|
SMTA
2542
DELISTED
Spirit MTA REIT Common Shares of Beneficial Interest
SMTA
| $1.04M | ﹤0.01% |
160,658
+75,905
| +90% | +$569K |
|
|
TRQ
2543
DELISTED
Turquoise Hill Resources Ltd
TRQ
| $1.04M | ﹤0.01% |
62,671
-43,078
| -41% | -$729K |
|
|
BRSL
2544
PUT
Brightstar Lottery PLC
BRSL
$2.1B
| $1.04M | ﹤0.01% |
80,000
+48,200
| +152% | +$742K |
|
2545
PUT
Tucows
TCX
$102M
| $1.04M | ﹤0.01% |
+12,800
| New | +$932K |
|
|
AMRN
2546
PUT
Amarin Corp
AMRN
$304M
| $1.04M | ﹤0.01% |
2,500
| – | – |
|
2547
Snap-on
SNA
$20.6B
| $1.04M | ﹤0.01% |
6,631
-19,387
| -75% | -$3.08M |
|
2548
Kinsale Capital Group
KNSL
$8.82B
| $1.04M | ﹤0.01% |
15,114
-605
| -4% | -$37.8K |
|
2549
Sumitomo Mitsui Financial
SMFG
$162B
| $1.04M | ﹤0.01% |
147,403
-725,225
| -83% | -$5.19M |
|
|
SYRS
2550
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $1.03M | ﹤0.01% |
11,269
+2,381
| +27% | +$166K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $2.66B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.